- Home
- LOOP vs TCRX Comparison
LOOP vs TCRX Comparison
Compare LOOP & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOOP
- TCRX
- Stock Information
- Founded
- LOOP 2010
- TCRX 2018
- Country
- LOOP Canada
- TCRX United States
- Employees
- LOOP N/A
- TCRX N/A
- Industry
- LOOP Major Chemicals
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- LOOP Industrials
- TCRX Health Care
- Exchange
- LOOP Nasdaq
- TCRX Nasdaq
- Market Cap
- LOOP 58.1M
- TCRX 64.1M
- IPO Year
- LOOP N/A
- TCRX 2021
- Fundamental
- Price
- LOOP $1.12
- TCRX $1.10
- Analyst Decision
- LOOP
- TCRX Strong Buy
- Analyst Count
- LOOP 0
- TCRX 7
- Target Price
- LOOP N/A
- TCRX $8.50
- AVG Volume (30 Days)
- LOOP 389.0K
- TCRX 1.1M
- Earning Date
- LOOP 01-13-2026
- TCRX 11-12-2025
- Dividend Yield
- LOOP N/A
- TCRX N/A
- EPS Growth
- LOOP N/A
- TCRX N/A
- EPS
- LOOP N/A
- TCRX N/A
- Revenue
- LOOP $11,112,000.00
- TCRX $8,423,000.00
- Revenue This Year
- LOOP N/A
- TCRX $255.18
- Revenue Next Year
- LOOP $777.41
- TCRX N/A
- P/E Ratio
- LOOP N/A
- TCRX N/A
- Revenue Growth
- LOOP 10901.98
- TCRX N/A
- 52 Week Low
- LOOP $0.85
- TCRX $0.91
- 52 Week High
- LOOP $2.29
- TCRX $4.94
- Technical
- Relative Strength Index (RSI)
- LOOP 39.67
- TCRX 37.83
- Support Level
- LOOP $0.91
- TCRX $0.91
- Resistance Level
- LOOP $1.17
- TCRX $1.02
- Average True Range (ATR)
- LOOP 0.12
- TCRX 0.11
- MACD
- LOOP -0.00
- TCRX 0.03
- Stochastic Oscillator
- LOOP 39.31
- TCRX 54.41
About LOOP Loop Industries Inc.
Loop Industries Inc. is a technology and licensing company whose mission is to accelerate the world's shift toward sustainable plastic and away from dependence on fossil fuels. The company owns patented and proprietary technology that depolymerizes no and low value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpet and polyester textile of any color, transparency or condition, and even ocean plastics that have been degraded by the sun and salt, to its base building blocks.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.